2,531 followers
Open Access UCL Research: Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials https://t.co/dD1UzAgRiv
Open Access UCL Research: Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials https://t.co/dD1UzAgRiv
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials | Alzheimer's Research & Therapy | Full Text https://t.co/BrNEffnfJI
Is this what happens when a drug name sounds like Beelzebub?... https://t.co/5bvGH9iQyu
Lack of efficacy- Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials https://t.co/IQGv2e4KX4